Dan Williams

CEO, SynaptixBio

Dan Williams has spent over 20 years in the industry after studying at the University of Dundee for a degree and a PhD in biochemistry and physiology. After his PhD, he entered the industry as a scientist and manager of a preclinical cell research group before moving into drug development. Later, he moved to Adaptimmune where he switched from biologics to cell therapies, setting up development groups and project managing preclinical research. He then became VP of Research Operations before co-founding SynaptixBio Ltd. in 2021 with the aim to push leukodystrophy therapies through to clinical trials.